EPZ011989 is primarily utilized in the field of cancer research, specifically targeting the EZH2 enzyme, which is known to play a critical role in the progression of certain cancers. By inhibiting EZH2, this compound helps in reducing the methylation of histone H3, thereby suppressing the growth of cancer cells. It is particularly effective in studies related to lymphomas and other malignancies where EZH2 mutations are prevalent. Researchers use EPZ011989 to better understand the mechanisms of EZH2 in tumorigenesis and to explore potential therapeutic strategies for treating cancers associated with this enzyme. Its application extends to preclinical studies where it aids in evaluating the efficacy of EZH2 inhibitors in various cancer models.